



Robert Greene Sterne
Edward J. Kessler
Jorge A. Goldstein
David K.S. Cornwell
Robert W. Esmond
Tracy-Gene G. Durkin
Michele A. Cimbalia
Michael B. Ray
Robert E. Sokohl
Eric K. Steffe
Michael Q. Lee
Steven R. Ludwig
John M. Covert
Linda E. Alcorn
Robert C. Millonig
Lawrence B. Bugaisky
Donald J. Featherstone
Michael V. Messinger

Judith U. Kim
Timothy J. Shea, Jr.
Patrick E. Garrett
Hedi L. Kraus
Edward W. Yee
Albert L. Ferro
Donald R. Banowitz
Peter A. Lockman
Molly A. McCall
Teresa U. Medler
Jeffrey S. Weaver
Kandrick P. Patterson
Vincent L. Capuano
Eklora Ellison Floyd
Thomas C. Fiala
Brian J. Del Buono
Virgil Lee Beaston
Kimberly N. Reddick

Theodore A. Wood
Elizabeth J. Haanes
Joseph S. Ostroff
Frank R. Cottingham
Christine M. Lhulier
Rae Lynn Prengaman
Jane Shershenovich
Lawrence J. Carroll
George S. Bardmesser
Daniel A. Klein
Jason D. Eisenberg
Michael D. Specht
Andrea J. Kamage
Tracy L. Muller
LuAnne M. Yuricek
John J. Figueroa
Ann E. Summerfield
Tiera S. Coston

Aric W. Ledford
Registered Patent Agents
Karen R. Markowicz
Nancy J. Leith
Helene C. Carlson
Gaby L. Longworth
Matthew J. Dowd
Aaron L. Schwartz
Mary B. Jung
Katriona Y. Pei Quach
Bryan L. Skeiton
Robert A. Schwartzman
Timothy A. Doyle
Jennifer R. Mahalingappa
Teresa A. Colella
Jeffrey S. Lundgren

Victoria S. Rutherford
Eric D. Hayes
Of Counsel
Kenneth C. Bass III
Evan R. Smith

*Admitted only in Maryland
*Admitted only in Virginia
*Practice Limited to Federal Agencies

January 15, 2004

WRITER'S DIRECT NUMBER:
(202) 772-8673
INTERNET ADDRESS:
JCOVERT@SKGF.COM

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Art Unit 1645

Re: U.S. Utility Patent Application
Application No. 10/668,326; Filed: September 24, 2003
For: **N-Substituted Hydromorphones and the Use Thereof**
Inventor: Donald J. Kyle
Our Ref: 1861.1640001/JMC/THN

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Information Disclosure Statement;
2. Form PTO-1449 (7 pages) citing twenty-one (21) references;
3. Copies of the twenty-one (21) cited references as listed on Form PTO-1449 (AR1-AT1; AR2-AT2; AR3-AT3; AR4-AT4; AR5-AT5; AR6-AT6; and AR7-AT7); and
4. Return postcard.


It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents
January 15, 2004
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency,
or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



John M. Covert
Attorney for Applicant
Registration No. 38,759

JMC/THN/KPQ/dms
Enclosures

218692-1



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re application of:

Donald J. Kyle

Appl. No.: 10/668,326

Filed: September 24, 2003

For: **N-Substituted Hydromorphones
and the Use Thereof**

Confirmation No: 2306

Art Unit: 1645

Examiner: *To Be Assigned*

Atty. Docket: 1861.1640001/JMC/THN

Information Disclosure Statement

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. Copies of documents AR1-AT7 are also provided.

Copies of documents AA1 to AD2 are not provided in accordance with the U.S. Patent and Trademark Office pre-OG notice of July 11, 2003, which states "[t]he Office hereby waives the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003."

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicant has listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicant reserves the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may

not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.


This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

~~It is respectfully requested that the Examiner initial and return a copy of the~~
enclosed PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.


John M. Covert
Attorney for Applicant
Registration No. 38,759

Date: Jan 15, 2004


1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1861.1640001/JMC/THN
FIRST NAMED INVENTOR
Donald J. Kyle
FILING DATE
September 24, 2003

APPLICATION NO.
10/668,326
ART UNIT
1645



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	TRADEMARK	DATE
	AA1	3,536,809	10/27/1970	Applezweig				02/17/1969
	AB1	3,598,123	08/10/1971	Zaffaroni				04/01/1969
	AC1	3,845,770	11/05/1974	Theeuwes <i>et al.</i>				06/05/1972
	AD1	3,916,899	11/04/1975	Theeuwes <i>et al.</i>				02/07/1974
	AE1	4,008,719	02/22/1977	Theeuwes <i>et al.</i>				02/02/1976
	AF1	5,059,595	10/22/1991	Le Grazie				03/20/1990
	AG1	5,073,543	12/17/1991	Marshall <i>et al.</i>				07/21/1988
	AH1	5,120,548	06/09/1992	McClelland <i>et al.</i>				11/07/1989
	AI1	5,354,556	10/11/1994	Sparks <i>et al.</i>				07/09/1990
	AJ1	5,591,767	01/07/1997	Mohr <i>et al.</i>				06/06/1995
	AK1	5,639,476	06/17/1997	Oshlack <i>et al.</i>				06/02/1995

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	1	Baumhaker, Y., and Sarne, Y., "Exposure of NG108-15 Cells to Etorphine Induces an Embedded State of the Opioid Receptor Which Discriminates Between Hydrophilic and Hydrophobic Ligands," <i>Pharmacology Communications</i> 7:149-155, Overseas Publishers Association and Harwood Academic Publishers (1996)
AS	1	Brent, P.J., "Behavioural Effect of Pretreatment with Opioid Antagonists and Sigma Binding Site Ligands on the Abnormal Motor Response Produced by the Kappa Opioid Agonist U50,488H in Guinea Pigs," <i>Neuropharmacology</i> 32:751-760, Pergamon Press (1993)
AT	1	Buchwald, H., <i>et al.</i> , "Long-term, continuous intravenous heparin administration by an implantable infusion pump in ambulatory patients with recurrent venous thrombosis," <i>Surgery</i> 88:507-516, The C.V. Mosby Company (1980)

EXAMINER

DATE CONSIDERED


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1861.1640001/JMC/THN
FIRST NAMED INVENTOR
Donald J. Kyle
FILING DATE
September 24, 2003

APPLICATION NO.
10/668,326
ART UNIT
1645

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA2	5,674,533	10/07/1997	Santus <i>et al.</i>			05/26/1995
	AB2	5,698,155	12/16/1997	Grosswald <i>et al.</i>			01/24/1995
	AC2	5,733,566	03/31/1998	Lewis			10/30/1995
	AD2	6,294,195 B1	09/25/2001	Oshlack <i>et al.</i>			09/07/1999
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	2	During, M.J., <i>et al.</i> , "Controlled Release of Dopamine from a Polymeric Brain Implant: In Vivo Characterization," <i>Ann. Neurol.</i> 25:351-356, Little, Brown and Company (1989)				
	AS	2	Foss, J.F., "A Review of the Potential Role of Methylalntrexone in Opioid Bowel Dysfunction," <i>Am. J. Surg.</i> 182(Suppl. To November 2001):19S-26S, Excerpta Medica, Inc. (November 2001)				
	AT	2	Goodson, J.M., "Dental Applications," in <i>Medical Applications of Controlled Release, Volume II Applications and Evaluation</i> , Langer, R.S., and Wise, D.L., ed., CRC Press, Inc., Boca Raton, FL, pp. 115-138 (1984)				

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 1861.1640001/JMC/THN FIRST NAMED INVENTOR Donald J. Kyle FILING DATE September 24, 2003	APPLICATION NO. 10/668,326 ART UNIT 1645	Page 3 of 7 
--	--	---	---	---

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						


FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes
							No
	AM						Yes
							No
	AN						Yes
							No
	AO						Yes
							No
	AP						Yes
							No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	<u>3</u>	Griffiths, S.P., <i>et al.</i> , "Heterogeneous Enantioselective Hydrogenation Catalysed by Platinum Modified by Some Morphine Alkaloids," in <i>Catalysis of Organic Reactions</i> , Herkes, F.E., ed., Marcel Dekker, Inc., New York, NY, pp. 89-100 (1998)
	AS	<u>3</u>	Howard III, M.A., <i>et al.</i> , "Intracerebral drug delivery in rats with lesion-induced memory deficits," <i>J. Neurosurg.</i> 71:105-112, American Association of Neurological Surgeons (1989)
	AT	<u>3</u>	Hunskaar, S., <i>et al.</i> , "Formalin test in mice, a useful technique for evaluating mild analgesics," <i>J. Neurosci. Meth.</i> 14:69-76, Elsevier Science Publishers B.V. (1985)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 1861.1640001/JMC/THN FIRST NAMED INVENTOR Donald J. Kyle FILING DATE September 24, 2003	APPLICATION NO. 10/668,326 ART UNIT 1645
--	--	---	---

Page 4 of 7



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>4</u>	Iorio, M.A., and Frigeni, V., "Narcotic agonist/antagonist properties of quaternary diastereoisomers derived from oxymorphone and naloxone," <i>Eur. J. Med. Chem. -Chim. Ther.</i> 19:301-303, Editions Scientifiques Elsevier (1984)
	AS	<u>4</u>	Langer, R., "New Methods of Drug Delivery," Science 249:1527-1533, American Association for the Advancement of Science (1990)
	AT	<u>4</u>	Langer, R., and Peppas, N., "Chemical and Physical Structure of Polymers as Carriers for Controlled Release of Bioactive Agents: A Review," <i>J. Macromol. Sci. Rev. Macromol. Chem. Phys.</i> C23:61-126, Marcel Dekker, Inc. (1983)


EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1861.1640001/JMC/THN
FIRST NAMED INVENTOR
Donald J. Kyle
FILING DATE
September 24, 2003

APPLICATION NO.
10/668,326
ART UNIT
1645

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AI						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>5</u>	Leander, J.D., "A Kappa Opioid Effect: Increased Urination in the Rat," <i>J. Pharmacol. Exp. Ther.</i> 224:89-94, The American Society for Pharmacology and Experimental Therapeutics (1983)
	AS	<u>5</u>	Levy, R.J., <i>et al.</i> , "Inhibition of Calcification of Bioprosthetic Heart Valves by Local Controlled-Release Diphosphonate," <i>Science</i> 228:190-192, American Association for the Advancement of Science (1985)
	AT	<u>5</u>	Milne, R.J., <i>et al.</i> , "Quaternary naloxone blocks morphine analgesia in spinal but not intact rats," <i>Neurosci. Lett.</i> 114:259-264, Elsevier Scientific Publishers Ireland Ltd. (1990)

EXAMINER

DATE CONSIDERED


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1861.1640001/JMC/THN
FIRST NAMED INVENTOR
Donald J. Kyle
FILING DATE
September 24, 2003

APPLICATION NO.
10/668,326
ART UNIT
1645



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA6						
	AB6						
	AC6						
	AD6						
	AE6						
	AF6						
	AG6						
	AH6						
	AI6						
	AJ6						
	AK6						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL6						Yes No
	AM6						Yes No
	AN6						Yes No
	AO6						Yes No
	AP6						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	6	Murphy, D.B., <i>et al.</i> , "Pharmacokinetic profile of epidurally administered methylnaltrexone, a novel peripheral opioid antagonist in a rabbit model," <i>Br. J. Anaesth.</i> 86:120-122, Oxford University Press (January 2001)
AS	6	Panerai, A.E., <i>et al.</i> , "Opiates Act Centrally on GH and PRL Release," <i>Endocrinology</i> 108:2400-2402, The Endocrine Society (1981)
AT	6	Saudek, C.D., <i>et al.</i> , "A Preliminary Trial of the Programmable Implantable Medication System for Insulin Delivery," <i>N. Engl. J. Med.</i> 321:574-579, Massachusetts Medical Society (1989)

EXAMINER

DATE CONSIDERED


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1861.1640001/JMC/THN
FIRST NAMED INVENTOR
Donald J. Kyle
FILING DATE
September 24, 2003

APPLICATION NO.
10/668,326
ART UNIT
1645

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA7						
	AB7						
	AC7						
	AD7						
	AE7						
	AF7						
	AG7						
	AH7						
	AI7						
	AJ7						
	AK7						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL7						Yes No
	AM7						Yes No
	AN7						Yes No
	AO7						Yes No
	AP7						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	<u>I</u>	Sefton, M.V., "Implantable Pumps," <i>Crit. Rev. Biomed. Eng.</i> 14:201-240, CRC Press (1987)
AS	<u>I</u>	Valle, L., <i>et al.</i> , "Effects of μ -opioid receptor agonists on intestinal secretion and permeability during acute intestinal inflammation in mice," <i>Eur. J. Pharmacol.</i> 389:235-242, Elsevier Science B.V. (2000)
AT	<u>I</u>	Yuan, C.-S., <i>et al.</i> , "Effects of Subcutaneous Methylalntrexone on Morphine-Induced Peripherally Mediated Side Effects: A Double-Blind Randomized Placebo-Controlled Trial," <i>J. Pharmacol. Exp. Ther.</i> 300:118-123, The American Society for Pharmacology and Experimental Therapeutics (January 2002)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.